
## Carlos Schönfeldt-Lecuona

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5816368/publications.pdf

Version: 2024-02-01



#	Article	IF	CITATIONS
1	Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS). Clinical Neurophysiology, 2014, 125, 2150-2206.	1.5	1,647
2	Using the International 10-20 EEG System for Positioning of Transcranial Magnetic Stimulation. Brain Topography, 2003, 16, 95-99.	1.8	848
3	Transcranial magnetic stimulation in therapy studies: examination of the reliability of "standard―coil positioning by neuronavigation. Biological Psychiatry, 2001, 50, 58-61.	1.3	330
4	Mechanisms and Applications of Theta-burst rTMS on the Human Motor Cortex. Brain Topography, 2010, 22, 294-306.	1.8	202
5	Antidepressant effects of augmentative transcranial magnetic stimulation. British Journal of Psychiatry, 2007, 191, 441-448.	2.8	174
6	Add-on rTMS for treatment of depression: a pilot study using stereotaxic coil-navigation according to PET data. Journal of Psychiatric Research, 2003, 37, 267-275.	3.1	112
7	Investigating directed influences between activated brain areas in a motor-response task using fMRI. Magnetic Resonance Imaging, 2006, 24, 181-185.	1.8	95
8	Stereotaxic rTMS for the treatment of auditory hallucinations in schizophrenia. NeuroReport, 2004, 15, 1669-1673.	1.2	94
9	Accuracy of Stereotaxic Positioning of Transcranial Magnetic Stimulation. Brain Topography, 2005, 17, 253-259.	1.8	84
10	Neurofilament light chain as a blood biomarker to differentiate psychiatric disorders from behavioural variant frontotemporal dementia. Journal of Psychiatric Research, 2019, 113, 137-140.	3.1	81
11	The value of neuronavigated rTMS for the treatment of depression. Neurophysiologie Clinique, 2010, 40, 37-43.	2.2	64
12	Intracortical excitability is modulated by a norepinephrine-reuptake inhibitor as measured with paired-pulse transcranial magnetic stimulation. Psychopharmacology, 2002, 164, 228-232.	3.1	54
13	From Imaging the Brain to Imaging the Retina: Optical Coherence Tomography (OCT) in Schizophrenia. Schizophrenia Bulletin, 2016, 42, sbv073.	4.3	52
14	Transcranial Magnetic Stimulation in Motor Conversion Disorder: A Short Case Series. Journal of Clinical Neurophysiology, 2006, 23, 473-476.	1.7	49
15	1-Hz rTMS in the treatment of tinnitus: A sham-controlled, randomized multicenter trial. Brain Stimulation, 2017, 10, 1112-1120.	1.6	38
16	Sham or real—Post hoc estimation of stimulation condition in a randomized transcranial magnetic stimulation trial. Neuroscience Letters, 2010, 471, 30-33.	2.1	35
17	Glial fibrillary acidic protein as blood biomarker for differential diagnosis and severity of major depressive disorder. Journal of Psychiatric Research, 2021, 144, 54-58.	3.1	34
18	Transcranial magnetic stimulation in depression – Lessons from the multicentre trials. Restorative Neurology and Neuroscience, 2010, 28, 569-576.	0.7	33

#	Article	IF	CITATIONS
19	Abuse of methylphenidate in Germany: Data from spontaneous reports of adverse drug reactions. Psychiatry Research, 2014, 215, 252-254.	3.3	31
20	Continuous theta-burst stimulation over the dorsal premotor cortex interferes with associative learning during object lifting. Cortex, 2009, 45, 473-482.	2.4	27
21	Exploring the affective component of pain perception during aversive stimulation in borderline personality disorder. Psychiatry Research, 2011, 186, 458-460.	3.3	27
22	Major depressive disorder: insight into candidate cerebrospinal fluid protein biomarkers from proteomics studies. Expert Review of Proteomics, 2017, 14, 499-514.	3.0	26
23	Retinal single-layer analysis with optical coherence tomography (OCT) in schizophrenia spectrum disorder. Schizophrenia Research, 2020, 219, 5-12.	2.0	25
24	Retinal changes in patients with major depressive disorder – A controlled optical coherence tomography study. Journal of Affective Disorders, 2018, 227, 665-671.	4.1	24
25	The neuroleptic malignant syndrome—a systematic case series analysis focusing on therapy regimes and outcome. Acta Psychiatrica Scandinavica, 2020, 142, 233-241.	4.5	24
26	Transcranial Magnetic Stimulation in the Reversal of Motor Conversion Disorder. Psychotherapy and Psychosomatics, 2003, 72, 286-288.	8.8	22
27	Depression, mitochondrial bioenergetics, and electroconvulsive therapy: a new approach towards personalized medicine in psychiatric treatment - a short review and current perspective. Translational Psychiatry, 2020, 10, 226.	4.8	22
28	Proteomic analysis reveals a biosignature of decreased synaptic protein in cerebrospinal fluid of major depressive disorder. Translational Psychiatry, 2020, 10, 144.	4.8	20
29	Treatment of the Neuroleptic Malignant Syndrome in International Therapy Guidelines: A Comparative Analysis. Pharmacopsychiatry, 2020, 53, 51-59.	3.3	18
30	Association between haemorrhages and treatment with selective and non-selective serotonergic antidepressants: Possible implications of quantitative signal detection. Psychiatry Research, 2015, 229, 257-263.	3.3	17
31	Non-Invasive Brain Stimulation in Conversion (Functional) Weakness and Paralysis: A Systematic Review and Future Perspectives. Frontiers in Neuroscience, 2016, 10, 140.	2.8	17
32	Subjective Reasons for Non-Reporting of Adverse Drug Reactions in a Sample of Physicians in Outpatient Care. Pharmacopsychiatry, 2016, 49, 57-61.	3.3	17
33	Relation of Promoter Methylation of the Oxytocin Gene to Stressful Life Events and Depression Severity. Journal of Molecular Neuroscience, 2020, 70, 201-211.	2.3	17
34	Psychological Distress, Fear and Coping Strategies During the Second and Third Waves of the COVID-19 Pandemic in Southern Germany. Frontiers in Psychiatry, 2022, 13, 860683.	2.6	17
35	Factors related to age at depression onset: the role of SLC6A4 methylation, sex, exposure to stressful life events and personality in a sample of inpatients suffering from major depression. BMC Psychiatry, 2021, 21, 167.	2.6	16
36	Effect of 1ÂHz Repetitive Transcranial Magnetic Stimulation Over the Auditory Cortex on Audiometry and Otoacustic Emissions. Brain Topography, 2012, 25, 241-247.	1.8	15

#	Article	IF	CITATIONS
37	Drugâ€Induced Liver Injury Associated With Antidepressive Psychopharmacotherapy: An Explorative Assessment Based on Quantitative Signal Detection Using Different MedDRA Terms. Journal of Clinical Pharmacology, 2016, 56, 769-778.	2.0	13
38	Risk of Bleeding Related to Selective and Non-selective Serotonergic Antidepressants: A Case/Non-case Approach Using Data from Two Pharmacovigilance Databases. Pharmacopsychiatry, 2015, 48, 19-24.	3.3	12
39	Extending the aceruloplasminemia phenotype: NBIA on imaging and acanthocytosis, yet only minor neurological findings. Journal of the Neurological Sciences, 2017, 376, 151-152.	0.6	10
40	Abuse liability of centrally acting non-opioid analgesics and muscle relaxants – a brief update based on a comparison of pharmacovigilance data and evidence from the literature. International Journal of Neuropsychopharmacology, 2014, 17, 957-959.	2.1	9
41	Hepatotoxicity associated with agomelatine and other antidepressants: Disproportionality analysis using pooled pharmacovigilance data from the Uppsala Monitoring Centre. Journal of Clinical Pharmacology, 2015, 55, 768-773.	2.0	9
42	The neural correlates of movement intentions: A pilot study comparing hypnotic and simulated paralysis. Consciousness and Cognition, 2015, 35, 158-170.	1.5	8
43	Arrhythmias related to antipsychotics and antidepressants: an analysis of the summaries of product characteristics of original products approved in Germany. European Journal of Clinical Pharmacology, 2021, 77, 767-775.	1.9	7
44	Incidence of inpatient cases with mental disorders due to use of cannabinoids in Germany: a nationwide evaluation. European Journal of Public Health, 2022, 32, 239-245.	0.3	7
45	From benzodiazepine to pregabalin dependence: Different agents, similar problems. Indian Journal of Psychiatry, 2015, 57, 111.	0.7	6
46	S-ketamine induces acute changes in the proteome of the mouse amygdala. Journal of Proteomics, 2020, 216, 103679.	2.4	6
47	Drug safety and adverse drug reaction reporting behavior related to outpatient opioid replacement therapy: Results from a survey among physicians. Journal of Substance Abuse Treatment, 2017, 74, 7-15.	2.8	5
48	Brain activity to transitional objects in patients with borderline personality disorder. Scientific Reports, 2017, 7, 13121.	3.3	5
49	Depressive Disorder With Panic Attacks After Replacement of an Intrauterine Device Containing Levonorgestrel: A Case Report. Frontiers in Psychiatry, 2020, 11, 561685.	2.6	5
50	Evidence and expert consensus based German guidelines for the use of repetitive transcranial magnetic stimulation in depression. World Journal of Biological Psychiatry, 2022, 23, 327-348.	2.6	4
51	Acute psychosis with a mediastinal carcinoma metastasis. Medical Science Monitor, 2005, 11, CS6-8.	1.1	4
52	Sensitivity of Quantitative Signal Detection in Regards to Pharmacological Neuroenhancement. International Journal of Molecular Sciences, 2017, 18, 101.	4.1	3
53	Intranasal Pregabalin Administration: A Review of the Literature and the Worldwide Spontaneous Reporting System of Adverse Drug Reactions. Brain Sciences, 2019, 9, 322.	2.3	3
54	Emotional Components of Pain Perception in Borderline Personality Disorder and Major Depression—A Repetitive Peripheral Magnetic Stimulation (rPMS) Study. Brain Sciences, 2020, 10, 905.	2.3	3

#	Article	IF	CITATIONS
55	Risk of Bleeding Associated with Antidepressant Drugs: The Competitive Impact of Antithrombotics in Quantitative Signal Detection. Drugs - Real World Outcomes, 2021, 8, 547-554.	1.6	3
56	Risk of Bleeding Associated With Antidepressants: Impact of Causality Assessment and Competition Bias on Signal Detection. Frontiers in Psychiatry, 2021, 12, 727687.	2.6	3
57	Rapid relapse in depression following initialization of oral contraception with ethinyl estradiol and chlormadinone acetate. General Hospital Psychiatry, 2014, 36, 230.e1-230.e2.	2.4	2
58	Psychiatrists' and dentists' knowledge and attitudes regarding adverse drug reactions of psychotropic drugs. Psychiatry Research, 2018, 266, 323-327.	3.3	2
59	Response letter: Retinal changes in patients with major depressive disorder - a controlled optical coherence tomography study. Journal of Affective Disorders, 2018, 239, 123.	4.1	2
60	Common Factors of Psychotherapy in Inpatients With Major Depressive Disorder: A Pilot Study. Frontiers in Psychiatry, 2019, 10, 463.	2.6	2
61	Pain perception in borderline personality disorder explored using PMS. European Psychiatry, 2011, 26, 1003-1003.	0.2	1
62	Successful Treatment of Major Depressive Disorder With Add-On Buprenorphine in a Patient With Previous Nonresponse to Standard Antidepressants. primary care companion for CNS disorders, The, 2017, 19, .	0.6	1
63	Plasminogen Activator Inhibitor – 1 Serum level in patients with major depressive disorder vs. healthy controls: a systematic review and meta-analysis. Trends in Psychiatry and Psychotherapy, 2021, , .	0.8	1
64	Liver failure under valproic acid. European Psychiatry, 2011, 26, 1282-1282.	0.2	0
65	Bone marrow, depressionâ€⊷ transmission of psychiatric diseases through hematologic stem cell transplantation ? - Aetilogic considerations and a clinical case report. European Psychiatry, 2011, 26, 704-704.	0.2	0
66	Pregabalin-associated Elevation of Clozapine Serum Levels. Pharmacopsychiatry, 2012, 45, e2-e2.	3.3	0
67	Risk of Bleeding Related to Selective and Non-selective Serotonergic Antidepressants: A Case/Non-case Approach Using Data from Two Pharmacovigilance Databases. Pharmacopsychiatry, 2015, 48, e1-e1.	3.3	0
68	EVIDENCE MAPS FOR DRUG THERAPY IN FRAIL OLDER ADULTS. Innovation in Aging, 2017, 1, 1321-1322.	0.1	0
69	Psychiatrische Notfallsituationen. , 2013, , 337-350.		0

70 Psychiatrische NotfÄte im Notfall- und Rettungswesen. , 2016, , 29-42.